NasdaqGM:ADMABiotechs
ADMA Biologics (ADMA) Margin Compression Challenges Bullish Growth Narrative In Q1 2026
ADMA Biologics (ADMA) opened 2026 with Q1 revenue of US$114.5 million and basic EPS of US$0.19, alongside trailing twelve month revenue of US$509.9 million and EPS of US$0.70. These figures frame the latest quarter in a broader earnings run rate. The company reported quarterly revenue of US$114.8 million in Q1 2025, US$139.2 million in Q4 2025, and US$114.5 million in Q1 2026. Over the same period, basic EPS moved from US$0.11 to US$0.21 and now stands at US$0.19. This sets up a results...